Cole G Bradley 4

What Happened

• Cole G. Bradley, a director of Castle Biosciences (CSTL), recorded a conversion/exercise of a derivative on May 22, 2026. The filing shows 13,667 units acquired through conversion and 13,667 shares listed as disposed at $0.00. The transaction is reported under derivative code M (exercise/conversion).
• The filing reports no cash proceeds (disposed at $0.00) — the document indicates these were Restricted Stock Units (RSUs) converting into common shares rather than an open-market sale or cash purchase.

Key Details

• Transaction date: 2026-05-22; filing date: 2026-05-27 (filed within the normal Form 4 reporting window).
• Shares converted/acquired: 13,667 RSUs → 13,667 common shares. Disposition: 13,667 shares at $0.00 (per filing).
• Shares owned after the transaction: not specified in the provided summary of the filing.
• Footnotes from the filing:
  • F1: Each RSU represents the right to receive one share of common stock.
  • F2: The RSUs vest in full on the earlier of (a) the one‑year anniversary of the grant date (May 22, 2026) or (b) the day immediately preceding the next annual meeting following the grant.
• Transaction code: M = exercise or conversion of a derivative instrument (RSU conversion here).
• No 10b5-1 plan, tax‑withholding or late‑filing indication is shown in the provided data.

Context

• This filing reflects conversion of RSUs into shares (a non‑cash event) rather than a purchase or sale indicating directional trading sentiment. Conversions like this are routine when equity awards vest or become deliverable.
• Retail investors should view this as an administrative equity award conversion unless subsequent filings show an open‑market sale or transfer of the resulting shares.